menu search

KNTE / Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why
Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%. Read More
Posted: Oct 3 2023, 11:16
Author Name: Zacks Investment Research
Views: 101819

KNTE News  

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

By Zacks Investment Research
October 3, 2023

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization more_horizontal

Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting

By GlobeNewsWire
March 14, 2023

Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting

SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision onco more_horizontal


Search within

Pages Search Results: